← All trials
NCT05641753
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 16, 2022
- Primary completion
- Jan 31, 2027
- Completion date
- Jan 31, 2027
- First posted
- Dec 8, 2022
- Last posted
- Dec 8, 2022
- Enrollment
- 125
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- New York UniversityLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- New York UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.